Many studies have reported an increased incidence of inhibitors in previously untreated patients (PUPs) with severe haemophilia A after the introduction of recombinant products. It was the objective of this study to investigate whether the inhibitor incidence has increased between 1990 and 2009 in an unselected cohort of PUPs with severe haemophilia A (FVIII<1 %). Patients were consecutively recruited from 31 haemophilia treatment centres in 16 countries and followed until 50 exposure days or until inhibitor development. Inhibitor development was studied in five-year birth cohorts comparing cumulative incidences. Furthermore the risk for inhibitor development per fiveyear birth cohort was studied using multivariable Cox regression, adjustin...
The age-adjusted incidence of new factor VIII inhibitors was analyzed in all United Kingdom patients...
The impact of treatment-related factors on inhibitor development in previously untreated patients (P...
Among the discussed risk factors for high-titre inhibitor (HRI) development in patients with hemophi...
Many studies have reported an increased incidence of inhibitors in previously untreated patients (PU...
The incidence of FIX inhibitors in severe hemophilia B (SHB) is not well defined. Frequencies of 3-5...
International audienceThe incidence of FIX inhibitors in severe hemophilia B (SHB) is not well defin...
Development of inhibitors is the most serious complication in haemophilia A treatment. The assessmen...
Introduction: Currently the most serious treatment complication of haemophilia is the inhibitor deve...
Background: Development of inhibitors is the most serious complication in haemophilia A treatment. T...
The development of factor VIII:C inhibitors remains one of the most serious complications of repeate...
Background: Development of inhibitors is the most serious complication in haemophilia A treatment. T...
Evidence about inhibitor formation in non-severe haemophilia and the potential role for clotting fac...
Essentials Data on product-related immunogenicity in previously treated haemophilia A patients is sc...
Inhibitor development represents the most serious side effect of haemophilia treatment. Any differen...
Evidence about inhibitor formation in non-severe haemophilia and the potential role for clotting fac...
The age-adjusted incidence of new factor VIII inhibitors was analyzed in all United Kingdom patients...
The impact of treatment-related factors on inhibitor development in previously untreated patients (P...
Among the discussed risk factors for high-titre inhibitor (HRI) development in patients with hemophi...
Many studies have reported an increased incidence of inhibitors in previously untreated patients (PU...
The incidence of FIX inhibitors in severe hemophilia B (SHB) is not well defined. Frequencies of 3-5...
International audienceThe incidence of FIX inhibitors in severe hemophilia B (SHB) is not well defin...
Development of inhibitors is the most serious complication in haemophilia A treatment. The assessmen...
Introduction: Currently the most serious treatment complication of haemophilia is the inhibitor deve...
Background: Development of inhibitors is the most serious complication in haemophilia A treatment. T...
The development of factor VIII:C inhibitors remains one of the most serious complications of repeate...
Background: Development of inhibitors is the most serious complication in haemophilia A treatment. T...
Evidence about inhibitor formation in non-severe haemophilia and the potential role for clotting fac...
Essentials Data on product-related immunogenicity in previously treated haemophilia A patients is sc...
Inhibitor development represents the most serious side effect of haemophilia treatment. Any differen...
Evidence about inhibitor formation in non-severe haemophilia and the potential role for clotting fac...
The age-adjusted incidence of new factor VIII inhibitors was analyzed in all United Kingdom patients...
The impact of treatment-related factors on inhibitor development in previously untreated patients (P...
Among the discussed risk factors for high-titre inhibitor (HRI) development in patients with hemophi...